 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes HALOPERIDOL increase or decrease the risk[0m
[34mof gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes HALOPERIDOL increase or decrease the risk[0m
[32mof gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"haloperidol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: HALOPERIDOL: adverse_reactions: There is no known effective treatment for tardive dyskinesia; antiparkinson agents usually do not alleviate the symptoms of this syndrome. It is suggested that[0m
[31mall antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, [0m
[31mthis syndrome may be masked. It has been reported that fine vermicular movement of the tongue may be an early sign of tardive dyskinesia and if the medication is stopped at that time, the full [0m
[31msyndrome may not develop. Tardive Dystonia Tardive dystonia, not associated with the above syndrome, has also been reported. Tardive dystonia is characterized by delayed onset of choreic or dystonic [0m
[31mmovements, is often persistent, and has the potential of becoming irreversible. HALOPERIDOL: adverse_reactions: Other CNS Effects Insomnia, restlessness, anxiety, euphoria, agitation, drowsiness, [0m
[31mdepression, lethargy, headache, confusion, vertigo, grand mal seizures, exacerbation of psychotic symptoms including hallucinations and catatonic-like behavioral states which may be responsive to drug[0m
[31mwithdrawal and/or treatment with anticholinergic drugs. Body as a Whole: Neuroleptic malignant syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m, hyperpyrexia and heat stroke have been reported with haloperidol. [0m[1;31m([0m[31mSee WARNINGS for [0m
[31mfurther information concerning NMS.[0m[1;31m)[0m[31m Hematologic Effects: Reports have appeared citing the occurrence of mild and usually transient leukopenia and leukocytosis, minimal decreases in red blood cell [0m
[31mcounts, anemia, or a tendency toward lymphomonocytosis. Agranulocytosis has rarely been reported to have occurred with the use of haloperidol, and then only in association with other medication. [0m
[31mHALOPERIDOL: adverse_reactions: Liver Effects: Impaired liver function and/or jaundice have been reported. Dermatologic Reactions: Maculopapular and acneiform skin reactions and isolated cases of [0m
[31mphotosensitivity and loss of hair. Endocrine Disorders: Lactation, breast engorgement, mastalgia, menstrual irregularities, gynecomastia, impotence, increased libido, hyperglycemia, hypoglycemia and [0m
[31mhyponatremia. Gastrointestinal Effects: Anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea and vomiting. Autonomic Reactions: Dry mouth, blurred vision, urinary retention, [0m
[31mdiaphoresis and priapism. Respiratory Effects: Laryngospasm, bronchospasm and increased depth of respiration. Special Senses: Cataracts, retinopathy and visual disturbances. HALOPERIDOL: [0m
[31madverse_reactions: Post-marketing Events Hyperammonemia has been reported in a [0m[1;31m5[0m[31m-[0m[1;31m1[0m[31mâ„[0m[1;31m2[0m[31m year old child with citrullinemia, an inherited disorder of ammonia excretion, following treatment with [0m
[31mhaloperidol.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: openfda: spl_set_id         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: geriatric_use: Geriatric Use Clinical studies of haloperidol did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from [0m
[31myounger subjects. Other reported clinical experience has not consistently identified differences in responses between the elderly and younger patients. However, the prevalence of tardive dyskinesia [0m
[31mappears to be highest among the elderly, especially elderly women [0m[1;31m([0m[31msee WARNINGS: Tardive Dyskinesia [0m[1;31m)[0m[31m. Also, the pharmacokinetics of haloperidol in geriatric patients generally warrants the use of [0m
[31mlower doses [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: openfda: package_ndc         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: openfda: pharm_class_epc         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: warnings: Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status [0m[1;31m([0m[31mincluding catatonic signs[0m[1;31m)[0m[31m and evidence of autonomic instability [0m[1;31m([0m[31mirregular [0m
[31mpulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias[0m[1;31m)[0m[31m. Additional signs may include elevated creatine phosphokinase, myoglobinuria [0m[1;31m([0m[31mrhabdomyolysis[0m[1;31m)[0m[31m and acute renal failure. The [0m
[31mdiagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness[0m
[1;31m([0m[31me.g., pneumonia, systemic infection, etc.[0m[1;31m)[0m[31m and untreated or inadequately treated extrapyramidal signs and symptoms [0m[1;31m([0m[31mEPS[0m[1;31m)[0m[31m. Other important considerations in the differential diagnosis include central [0m
[31manticholinergic toxicity, heat stroke, drug fever and primary central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m pathology. HALOPERIDOL: warnings: The management of NMS should include [0m[1;31m1[0m[1;31m)[0m[31m immediate discontinuation of [0m
[31mantipsychotic drugs and other drugs not essential to concurrent therapy, [0m[1;31m2[0m[1;31m)[0m[31m intensive symptomatic treatment and medical monitoring, and [0m[1;31m3[0m[1;31m)[0m[31m treatment of any concomitant serious medical problems for [0m
[31mwhich specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after[0m
[31mrecovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Hyperpyrexia and[0m
[31mheat stroke, not associated with the above symptom complex, have also been reported with haloperidol. Falls Haloperidol tablets, USP may cause somnolence, postural hypotension, motor and sensory [0m
[31minstability, which may lead to falls and, consequently, fractures or other injuries. HALOPERIDOL: warnings: For patients with diseases, conditions, or medications that could exacerbate these effects, [0m
[31mcomplete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy. Usage in Pregnancy Pregnancy Nonteratogenic Effects Neonates [0m
[31mexposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, [0m
[31mhypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other [0m
[31mcases neonates have required intensive care unit support and prolonged hospitalization. Haloperidol should be used during pregnancy only if the potential benefit justifies the potential risk to the [0m
[31mfetus. HALOPERIDOL: warnings: Rodents given [0m[1;31m2[0m[31m to [0m[1;31m20[0m[31m times the usual maximum human dose of haloperidol by oral or parenteral routes showed an increase in incidence of resorption, reduced fertility, [0m
[31mdelayed delivery and pup mortality. No teratogenic effect has been reported in rats, rabbits or dogs at dosages within this range, but cleft palate has been observed in mice given [0m[1;31m15[0m[31m times the usual [0m
[31mmaximum human dose. Cleft palate in mice appears to be a nonspecific response to stress or nutritional imbalance as well as to a variety of drugs, and there is no evidence to relate this phenomenon to[0m
[31mpredictable human risk for most of these agents. There are no well controlled studies with haloperidol in pregnant women. There are reports, however, of cases of limb malformations observed following [0m
[31mmaternal use of haloperidol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. [0m
[31mHALOPERIDOL: warnings: Since such experience does not exclude the possibility of fetal damage due to haloperidol, this drug should be used during pregnancy or in women likely to become pregnant only [0m
[31mif the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment. Combined Use of Haloperidol and Lithium An encephalopathic syndrome [0m[1;31m([0m[31mcharacterized [0m
[31mby weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS[0m[1;31m)[0m[31m followed by irreversible brain damage has occurred in a few [0m
[31mpatients treated with lithium plus haloperidol. A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients [0m
[31mreceiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: precautions: Therefore, although not optimal, this study does suggest the absence of a haloperidol related increase in the incidence of neoplasia in rats at doses up to [0m[1;31m20[0m[31m times [0m
[31mthe usual daily human dose for chronic or resistant patients. In female mice at [0m[1;31m5[0m[31m and [0m[1;31m20[0m[31m times the highest initial daily dose for chronic or resistant patients, there was a statistically significant [0m
[31mincrease in mammary gland neoplasia and total tumor incidence; at [0m[1;31m20[0m[31m times the same daily dose there was a statistically significant increase in pituitary gland neoplasia. In male mice, no [0m
[31mstatistically significant differences in incidences of total tumors or specific tumor types were noted. Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic [0m
[31madministration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these[0m
[31mdrugs is contemplated in a patient with a previously detected breast cancer. HALOPERIDOL: precautions: Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been [0m
[31mreported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of [0m
[31mantipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; [0m
[31mthe available evidence is considered too limited to be conclusive at this time. There are no well controlled studies with haloperidol in pregnant women. There are reports, however, of cases of limb [0m
[31mmalformations observed following maternal use of haloperidol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not [0m
[31mestablished in these cases. HALOPERIDOL: precautions: Since such experience does not exclude the possibility of fetal damage due to haloperidol, this drug should be used during pregnancy or in women [0m
[31mlikely to become pregnant only if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment. Pediatric Use Safety and effectiveness in pediatric [0m
[31mpatients have not been established. Geriatric Use Clinical studies of haloperidol did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from [0m
[31myounger subjects. Other reported clinical experience has not consistently identified differences in responses between the elderly and younger patients. However, the prevalence of tardive dyskinesia [0m
[31mappears to be highest among the elderly, especially elderly women [0m[1;31m([0m[31msee WARNINGS: Tardive Dyskinesia [0m[1;31m)[0m[31m. Also, the pharmacokinetics of haloperidol in geriatric patients generally warrants the use of [0m
[31mlower doses [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: general_precautions: General A number of cases of bronchopneumonia, some fatal, have followed the use of antipsychotic drugs, including haloperidol. It has been postulated that [0m
[31mlethargy and decreased sensation of thirst due to central inhibition may lead to dehydration, hemoconcentration and reduced pulmonary ventilation. Therefore, if the above signs and symptoms appear, [0m
[31mespecially in the elderly, the physician should institute remedial therapy promptly. Although not reported with haloperidol, decreased serum cholesterol and/or cutaneous and ocular changes have been [0m
[31mreported in patients receiving chemically-related drugs. Haloperidol may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or [0m
[31mdriving a motor vehicle. The ambulatory patient should be warned accordingly. The use of alcohol with this drug should be avoided due to possible additive effects and hypotension.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: clinical_pharmacology: CLINICAL PHARMACOLOGY The precise mechanism of action has not been clearly established.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: openfda: spl_id         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: openfda: product_ndc         [0m
[31mSOURCE:HALOPERIDOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the HALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label does list [0m
[32mgastrointestinal effects such as anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but it does not directly link HALOPERIDOL to gastrointestinal [0m
[32mulcer hospitalization.[0m
[32mSOURCE: HALOPERIDOL label[0m
[32mEXTRACT_START_END: Gastrointestinal Effects: Anorexia, constipation[0m[32m...[0m[32mnausea and vomiting.[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the [0m
[34mHALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label does list gastrointestinal effects such as anorexia, [0m
[34mconstipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but it does not directly link HALOPERIDOL to gastrointestinal ulcer hospitalization.[0m
[34mSOURCE: HALOPERIDOL label[0m
[34mEXTRACT_START_END: Gastrointestinal Effects: Anorexia, constipation[0m[34m...[0m[34mnausea and vomiting.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the HALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label lists gastrointestinal [0m
[32meffects such as anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but does not directly link HALOPERIDOL to gastrointestinal ulcer [0m
[32mhospitalization."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the HALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label lists gastrointestinal [0m
[34meffects such as anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but does not directly link HALOPERIDOL to gastrointestinal ulcer [0m
[34mhospitalization."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of gastrointestinal ulcer hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that the HALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label lists gastrointestinal effects[0m
[31msuch as anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but does not directly link HALOPERIDOL to gastrointestinal ulcer hospitalization.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for HALOPERIDOL does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. While the label lists gastrointestinal effects such as [0m
[32manorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, it does not directly link HALOPERIDOL to gastrointestinal ulcer hospitalization. Therefore, we [0m
[32mcannot determine from the FDA label whether HALOPERIDOL affects the risk of gastrointestinal ulcer hospitalization.[0m
